Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
To investigate the relationship between the pharmacokinetics and pharmacodynamics of
UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).